Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2025-A01044-45 | Other Identifier | APHM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hematological malignancy is a disease of the blood. In some cases, this pathology requires therapeutic management, which is not necessarily the case for you. Nevertheless, to improve the management of patients who need it, we are conducting research to assess the state of your immune system. Indeed, the role of the immune system is not limited to controlling infections, but is also important in controlling the proliferation of cancer cells, in hematology as in other types of cancer. Your immune system can play a spontaneous anti-tumor control role, but some so-called "immunotherapy" treatments aim to destroy cancer cells by stimulating the immune system, restoring its capabilities, and directing the immune response against tumor cells. For this immunotherapy treatment to be effective, since it uses your own immune cells (in most cases), these cells must be in a state to respond and be able to destroy the tumor. It is this ability to activate immune cells that is tested in this research protocol, using a simple test that could in future be used in routine clinical practice. But to understand why these immune cells don't work, we will also have to carry out genetic tests to analyze the various molecules that could interfere with the immune response, and try to inhibit the molecules that prevent the immune response.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| blood sampling | Experimental | blood sampling in patients with hematological malignancies |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| blood sampling | Other | Additional blood sampling as part of routine care |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentages of immune effectors | Percentages of immune effectors responding to stimulation, assessed in patients with hematological malignancies | At the enrollement in the study |
| Measure | Description | Time Frame |
|---|---|---|
| Activation percentages (cytometry) vs. polymorphism expression percentage (molecular biology) | Analysis and comparison of activation percentages (cytometry) vs. polymorphism expression percentage (molecular biology) | At the enrollement |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Person in a period of exclusion from another research protocol at the time the non-opposition is signed.
Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code, i.e. :
A person who cannot read and understand the French language well enough to be able to consent to take part in research.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Régis Costello Pr | Contact | 0491435817 | 33 | promotion.interne@ap-hm.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assisitance Publique HĂ´pitaux de Marseille | Marseille | 13005 | France |
Not provided
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |